Cargando…

Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatment

Cutaneous T-cell lymphomas (CTCLs) are a spectrum of diseases with varied clinical courses caused by malignant clonal proliferation of skin-tropic T cells. Most patients have an indolent disease course managed with skin-directed therapies. In contrast, others, especially in advanced stages of diseas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borcherding, Nicholas, Severson, Kevin J., Henderson, Nicholas, Ortolan, Luana S., Rosenthal, Allison C., Bellizzi, Andrew M., Liu, Vincent, Link, Brian K., Mangold, Aaron R., Jabbari, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881051/ https://www.ncbi.nlm.nih.gov/pubmed/35390145 http://dx.doi.org/10.1182/bloodadvances.2021005991

Ejemplares similares

Sézary syndrome originates from heavily mutated hematopoietic progenitors
por: Harro, Carly M., et al.
Publicado: (2023)

Sézary syndrome patient–derived models allow drug selection for personalized therapy
por: Gallardo, Fernando, et al.
Publicado: (2022)

CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome
por: Vergnolle, Inès, et al.
Publicado: (2022)

Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers
por: Rodríguez, Marta, et al.
Publicado: (2021)

Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity
por: Le, Kang, et al.
Publicado: (2023)

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
por: Gouni, Sushanth, et al.
Publicado: (2022)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
por: Ansari-Pour, Naser, et al.
Publicado: (2023)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
por: Tun, Aung M., et al.
Publicado: (2022)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor
por: Gomez, Eliana B., et al.
Publicado: (2023)

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey
por: Harkins, R. Andrew, et al.
Publicado: (2022)

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
por: Thijssen, Rachel, et al.
Publicado: (2022)

HGAL inhibits lymphoma dissemination by interacting with multiple cytoskeletal proteins
por: Jiang, Xiaoyu, et al.
Publicado: (2021)

Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21
por: Zaaboub, Rim, et al.
Publicado: (2022)

Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies
por: Dong, Zhenyuan, et al.
Publicado: (2022)

Next-generation sequencing–based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL
por: Miljkovic, Milos D., et al.
Publicado: (2021)

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma
por: Yao, Yao, et al.
Publicado: (2023)

A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile
por: Salmeron-Villalobos, Julia, et al.
Publicado: (2022)

Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations
por: Koh, Jiwon, et al.
Publicado: (2021)

Genetic and immunohistochemical profiling of NK/T-cell lymphomas reveals prognostically relevant BCOR-MYC association
por: Oishi, Naoki, et al.
Publicado: (2022)

Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL
por: Mazzara, Saveria, et al.
Publicado: (2022)

Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma
por: Merz, Maximilian, et al.
Publicado: (2022)

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023)

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
por: Short, Nicholas J., et al.
Publicado: (2022)

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
por: Griffin, Rosalie, et al.
Publicado: (2023)

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma
por: Lakhotia, Rahul, et al.
Publicado: (2022)

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
por: Bewicke-Copley, Findlay, et al.
Publicado: (2022)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma
por: Barnell, Erica K., et al.
Publicado: (2022)

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
por: Major, Ajay, et al.
Publicado: (2023)

Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL
por: Levinson, Anya L., et al.
Publicado: (2023)

Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models
por: Wu, Chi-Heng, et al.
Publicado: (2022)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
por: Geyer, Mark B., et al.
Publicado: (2023)

Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma
por: Daenthanasanmak, Anusara, et al.
Publicado: (2022)

Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study
por: Böttcher, Sebastian, et al.
Publicado: (2022)

Outcomes after biochemical or clinical progression in patients with multiple myeloma
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_58i7mdt0madtaldst4n0f1a9ki